Novartis vs SCTbio: CDMO Comparison
How does Novartis compare to SCTbio for CAR-T manufacturing?
Side-by-side comparison of Novartis and SCTbio on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Novartis has more FDA inspections on record (15 vs 0) — a deeper regulatory paper trail.
- Novartis has materially broader EMA GMP coverage (59 active certificates vs 5) — stronger EU footprint.
- Novartis maintains 3 MHRA / UK GMP certificates; SCTbio does not.
- Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Novartis and SCTbio qualify as CAR-T manufacturers; Novartis carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both Novartis and SCTbio qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Novartis vs SCTbio
How does Novartis compare to SCTbio for CAR-T manufacturing?
On CDMO Signal's composite Signal Score, Novartis is 88/100 and SCTbio is 82/100; Novartis has 15 FDA inspections on record vs 0 for SCTbio; European coverage is 62 active EMA+MHRA certificates for Novartis vs 5 for SCTbio. Both are tracked in the CDMO Signal directory as CAR-T CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Novartis or SCTbio?
Novartis has 15 FDA inspections on record (NAI 6 / VAI 7 / OAI 2) and 0 warning letters. SCTbio has 0 FDA inspections on record (NAI 0 / VAI 0 / OAI 0) and 0 warning letters.
How do Novartis and SCTbio compare on European GMP coverage?
Novartis holds 59 active EMA GMP certificates and 3 MHRA / UK certificates. SCTbio holds 5 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Novartis or SCTbio?
Novartis is matched to 137 ClinicalTrials.gov records as a manufacturing partner; SCTbio is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for CAR-T manufacturing — Novartis or SCTbio?
Both Novartis and SCTbio are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →